uniQure (NASDAQ:QURE) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of uniQure (NASDAQ:QURE) have been given a consensus recommendation of “Moderate Buy” by the six brokerages that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $17.00.

Several research analysts have weighed in on QURE shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $28.00 price objective on shares of uniQure in a research report on Wednesday, November 6th. StockNews.com upgraded shares of uniQure to a “sell” rating in a research note on Thursday, October 17th. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research note on Wednesday, November 6th. Royal Bank of Canada decreased their target price on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Finally, The Goldman Sachs Group lowered their target price on shares of uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a report on Wednesday, November 6th.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in QURE. RTW Investments LP bought a new stake in uniQure during the third quarter worth $49,000. China Universal Asset Management Co. Ltd. lifted its position in shares of uniQure by 57.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after buying an additional 3,663 shares during the last quarter. Atria Investments Inc bought a new position in uniQure in the third quarter valued at about $53,000. Quarry LP acquired a new position in uniQure during the third quarter worth about $58,000. Finally, Vanguard Personalized Indexing Management LLC raised its stake in uniQure by 21.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 2,306 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

uniQure Stock Up 1.0 %

uniQure stock opened at $6.05 on Wednesday. The company’s 50-day moving average price is $5.95 and its two-hundred day moving average price is $5.98. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock has a market cap of $294.90 million, a P/E ratio of -1.22 and a beta of 0.90. uniQure has a twelve month low of $3.73 and a twelve month high of $11.35.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.21. The company had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. As a group, analysts expect that uniQure will post -3.81 EPS for the current year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.